Crown Bioscience has been selected by Pierre Fabre Research Institute as one of their partners to advance their immuno-oncology drug discovery pipeline.

CrownBio will leverage its collection of patient-derived xenograft (PDX) models and humanized solutions for immuno-oncology drug development to engraft PDX models selected by Pierre Fabre into CD34+ humanized mouse models. These customized, humanized models will be used to help accelerate Pierre Fabre’s innovative immuno-oncology drug discovery pipeline.

“Pierre Fabre recognizes the value of CrownBio’s extensive PDX collection and their expertise in implementing innovative humanization strategies,” said Nathalie Corvaia, Pierre Fabre’s Head of New Biologic Entity Platform and Director of Center of Immunology R&D Pierre Fabre. “We have chosen them as our partner for these reasons and look forward to what we are confident will be a successful alliance.”  

“We are very pleased that Pierre Fabre has selected us as a trusted partner to advance their cutting-edge immuno-oncology pipeline,” said Jean-Pierre Wery, CrownBio’s chief executive officer. “Our unique capabilities will enable Pierre Fabre to continue providing new and improved therapies for the treatment of cancer.”